These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 26827962)
1. Vitamin D Signaling Modulators in Cancer Therapy. Luo W; Johnson CS; Trump DL Vitam Horm; 2016; 100():433-72. PubMed ID: 26827962 [TBL] [Abstract][Full Text] [Related]
2. Dimethyl fumarate and vitamin D derivatives cooperatively enhance VDR and Nrf2 signaling in differentiating AML cells in vitro and inhibit leukemia progression in a xenograft mouse model. Nachliely M; Trachtenberg A; Khalfin B; Nalbandyan K; Cohen-Lahav M; Yasuda K; Sakaki T; Kutner A; Danilenko M J Steroid Biochem Mol Biol; 2019 Apr; 188():8-16. PubMed ID: 30508646 [TBL] [Abstract][Full Text] [Related]
3. 1α,25-dihydroxyvitamin D3 and rosiglitazone synergistically enhance osteoblast-mediated mineralization. Woeckel VJ; Bruedigam C; Koedam M; Chiba H; van der Eerden BC; van Leeuwen JP Gene; 2013 Jan; 512(2):438-43. PubMed ID: 22967709 [TBL] [Abstract][Full Text] [Related]
4. Vitamin D receptor activation reduces VCaP xenograft tumor growth and counteracts ERG activity despite induction of TMPRSS2:ERG. Roberts JM; Martin RS; Piyarathna DB; MacKrell JG; Rocha GV; Dodge JA; Coarfa C; Krishnan V; Rowley DR; Weigel NL Oncotarget; 2017 Jul; 8(27):44447-44464. PubMed ID: 28591703 [TBL] [Abstract][Full Text] [Related]
5. Involvement of 1,25D3-MARRS (membrane associated, rapid response steroid-binding), a novel vitamin D receptor, in growth inhibition of breast cancer cells. Richard CL; Farach-Carson MC; Rohe B; Nemere I; Meckling KA Exp Cell Res; 2010 Mar; 316(5):695-703. PubMed ID: 20036234 [TBL] [Abstract][Full Text] [Related]
6. The prostate cancer TMPRSS2:ERG fusion synergizes with the vitamin D receptor (VDR) to induce CYP24A1 expression-limiting VDR signaling. Kim JS; Roberts JM; Bingman WE; Shao L; Wang J; Ittmann MM; Weigel NL Endocrinology; 2014 Sep; 155(9):3262-73. PubMed ID: 24926821 [TBL] [Abstract][Full Text] [Related]
7. VDR activity is differentially affected by Hic-5 in prostate cancer and stromal cells. Solomon JD; Heitzer MD; Liu TT; Beumer JH; Parise RA; Normolle DP; Leach DA; Buchanan G; DeFranco DB Mol Cancer Res; 2014 Aug; 12(8):1166-80. PubMed ID: 24825850 [TBL] [Abstract][Full Text] [Related]
8. Differential response of lung cancer cell lines to vitamin D derivatives depending on EGFR, KRAS, p53 mutation status and VDR polymorphism. Maj E; Trynda J; Maj B; Gębura K; Bogunia-Kubik K; Chodyński M; Kutner A; Wietrzyk J J Steroid Biochem Mol Biol; 2019 Oct; 193():105431. PubMed ID: 31326626 [TBL] [Abstract][Full Text] [Related]
9. The aryl hydrocarbon receptor activator benzo[a]pyrene enhances vitamin D3 catabolism in macrophages. Matsunawa M; Amano Y; Endo K; Uno S; Sakaki T; Yamada S; Makishima M Toxicol Sci; 2009 May; 109(1):50-8. PubMed ID: 19244278 [TBL] [Abstract][Full Text] [Related]
10. VDR microRNA expression and epigenetic silencing of vitamin D signaling in melanoma cells. Essa S; Denzer N; Mahlknecht U; Klein R; Collnot EM; Tilgen W; Reichrath J J Steroid Biochem Mol Biol; 2010 Jul; 121(1-2):110-3. PubMed ID: 20153427 [TBL] [Abstract][Full Text] [Related]
11. Vitamin D in thyroid tumorigenesis and development. Clinckspoor I; Verlinden L; Mathieu C; Bouillon R; Verstuyf A; Decallonne B Prog Histochem Cytochem; 2013 Aug; 48(2):65-98. PubMed ID: 23890557 [TBL] [Abstract][Full Text] [Related]
12. Altered pharmacokinetics of 1alpha,25-dihydroxyvitamin D3 and 25-hydroxyvitamin D3 in the blood and tissues of the 25-hydroxyvitamin D-24-hydroxylase (Cyp24a1) null mouse. Masuda S; Byford V; Arabian A; Sakai Y; Demay MB; St-Arnaud R; Jones G Endocrinology; 2005 Feb; 146(2):825-34. PubMed ID: 15498883 [TBL] [Abstract][Full Text] [Related]
13. Cross-talk between vitamin D receptor (VDR)- and peroxisome proliferator-activated receptor (PPAR)-signaling in melanoma cells. Sertznig P; Dunlop T; Seifert M; Tilgen W; Reichrath J Anticancer Res; 2009 Sep; 29(9):3647-58. PubMed ID: 19667161 [TBL] [Abstract][Full Text] [Related]
14. Signaling pathways for vitamin D-induced differentiation: implications for therapy of proliferative and neoplastic diseases. Studzinski GP; McLane JA; Uskoković MR Crit Rev Eukaryot Gene Expr; 1993; 3(4):279-312. PubMed ID: 8286848 [TBL] [Abstract][Full Text] [Related]
15. Vitamin D Analogs Regulate the Vitamin D System and Cell Viability in Ovarian Cancer Cells. Piatek K; Kutner A; Cacsire Castillo-Tong D; Manhardt T; Kupper N; Nowak U; Chodyński M; Marcinkowska E; Kallay E; Schepelmann M Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008598 [TBL] [Abstract][Full Text] [Related]
16. Vitamin D receptor (VDR) regulation of voltage-gated chloride channels by ligands preferring a VDR-alternative pocket (VDR-AP). Menegaz D; Mizwicki MT; Barrientos-Duran A; Chen N; Henry HL; Norman AW Mol Endocrinol; 2011 Aug; 25(8):1289-300. PubMed ID: 21659475 [TBL] [Abstract][Full Text] [Related]
17. Snail-1 regulates VDR signaling and inhibits 1,25(OH)-D₃ action in osteosarcoma. Yang H; Zhang Y; Zhou Z; Jiang X; Shen A Eur J Pharmacol; 2011 Nov; 670(2-3):341-6. PubMed ID: 21963453 [TBL] [Abstract][Full Text] [Related]
18. RIPK1 binds to vitamin D receptor and decreases vitamin D-induced growth suppression. Quarni W; Lungchukiet P; Tse A; Wang P; Sun Y; Kasiappan R; Wu JY; Zhang X; Bai W J Steroid Biochem Mol Biol; 2017 Oct; 173():157-167. PubMed ID: 28159673 [TBL] [Abstract][Full Text] [Related]
19. CYP24A1 as a potential target for cancer therapy. Sakaki T; Yasuda K; Kittaka A; Yamamoto K; Chen TC Anticancer Agents Med Chem; 2014 Jan; 14(1):97-108. PubMed ID: 23869781 [TBL] [Abstract][Full Text] [Related]
20. Vitamin D Bunch BL; Ma Y; Attwood K; Amable L; Luo W; Morrison C; Guru KA; Woloszynska-Read A; Hershberger PA; Trump DL; Johnson CS Cancer Med; 2019 May; 8(5):2449-2461. PubMed ID: 30972950 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]